Clinical impact of skeletal muscle area in patients with non-small cell lung cancer treated with anti-PD-1 inhibitors

Kazuki Takada, Yasuto Yoneshima, Kentaro Tanaka, Isamu Okamoto, Mototsugu Shimokawa, Sho Wakasu, Shinkichi Takamori, Gouji Toyokawa, Taro Oba, Atsushi Osoegawa, Tetsuzo Tagawa, Yoshinao Oda, Yoichi Nakanishi, Masaki Mori

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)

Abstract

Purpose: The aim of this study was to elucidate the clinical impact of skeletal muscle area (SMA) in patients with non-small cell lung cancer (NSCLC) treated with anti-programmed cell death-1 (PD-1) inhibitors. Methods: Univariate and multivariate analyses were performed on data of 103 patients with advanced or recurrent NSCLC treated with anti-PD-1 inhibitors. The SMA was measured at the level of the third lumbar vertebral (L3) on computed tomography images using OsiriX software (32-bit, version 5.8; OsiriX, Geneva, Switzerland). The L3 muscle index (cm2/m2) was defined as the SMA (cm2) at the L3 level divided by the height (m) squared. Results: L3 muscle index Low was an independent predictor of both progression-free (P = 0.0399) and overall survival (P = 0.0155). Moreover, the disease control rate was significantly lower in the L3 muscle index Low group (49.0% [25/51]) than in the L3 muscle index High group (73.1% [38/52]; P = 0.0117). However, there was no significant difference between the response rates of the L3 muscle index Low group (21.6% [11/51]) and L3 muscle index High group (32.7% [17/52]; P = 0.2031). Conclusions: L3 muscle index Low is an independent predictor of worse outcomes in NSCLC patients treated with anti-PD-1 inhibitors.

Original languageEnglish
Pages (from-to)1217-1225
Number of pages9
JournalJournal of Cancer Research and Clinical Oncology
Volume146
Issue number5
DOIs
Publication statusPublished - May 1 2020

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Clinical impact of skeletal muscle area in patients with non-small cell lung cancer treated with anti-PD-1 inhibitors'. Together they form a unique fingerprint.

Cite this